

Supplementary Data

Specific interactions between the *Candida albicans* ABC transporter Cdr1p ectodomain and a D-octapeptide derivative inhibitor

Kyoko Niimi¹, David R. K. Harding², Ann R. Holmes¹, Erwin Lamping¹, Masakazu Niimi^{1,3}, Joel D. A. Tyndall⁴, Richard D. Cannon¹ and Brian C. Monk^{1*}

¹The Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealand. ²The Centre for Separation Science, Massey University, Palmerston North, New Zealand. ³Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo, Japan. ⁴National School of Pharmacy, University of Otago, Dunedin, New Zealand.

***Corresponding author:** Department of Oral Sciences and the Sir John Walsh Research Institute, School of Dentistry, University of Otago, P.O. Box 647, 310 Great King Steet, Dunedin, New Zealand

Tel: +64 3 479 7099, Fax: +64 3 479 7078

Email: brian.monk@otago.ac.nz

Figure legends

Fig S1. Checkerboard assays for *Saccharomyces cerevisiae* strains overexpressing *S. cerevisiae* Pdr5p and heterologous proteins from *Candida albicans* (Ca) or *C. glabrata* (Cg). A, AD/PDR5; B, AD/CaCDR2; C, AD/CgCDR1; D, AD/CgCDR2; E, AD/CaMDR1; F, AD/CaERG11. Checkerboard assays were carried out as described in Experimental Procedures.

Fig S2. Checkerboard assays for isogenic *Candida albicans* strains. A, CAI4; B, MML33 (homozygous *CDR1* deletant). Checkerboard assays were carried out as described in Experimental Procedures.

Fig S3. TRITC-labeled RC21, RC22 and RCC3 are excluded from yeast. Yeast strains (AD/pABC3 or AD/CDR1-EGFP) were grown in CSM medium at pH 6.8 to mid-log phase ($OD_{600nm} = 1$), washed by centrifugation and then incubated in 10 μ M TRITC-labeled RC21, RC22 or RC23 in fresh CSM medium for 5 minutes at room temperature and viewed by confocal microscopy.

Fig S4. RC21 does not appear to affect the folding or localization of CaCdr1p-EGFP chimeras. An overnight culture of AD/CDR1-EGFP cells was grown in fresh CSM medium at pH 6.8 from 0.1 OD_{600nm} for 6 h in the presence or absence of 2.5 μ M RC21v3. The cells were grown to the same density in this time (~ 1.0 OD_{600nm}) and viewed by confocal microscopy as a series of z-sections.

Fig S5. Inhibition of wild type and RC21 chemosensitization suppressor mutant CaCdr1p by RC21v3. Plasma membranes were prepared and CaCdr1p ATPase activity determined at pH 7.5 without ATP protection as described in Experimental Procedures. The RC21 chemosensitization suppressor mutants are affected by the mutations described in Table S1.

Fig S1




Fig S2




Fig S3





Fig S4

AD/CDR1-EGFP
(control)



AD/CDR1-EGFP
+2.5 μ M RC21v3




Fig S5




Table S1

IC₅₀ of RC21v3 for Cdr1p-ATPase activity in plasma membrane fractions prepared from RC21 chemosensitization suppressor mutants

Strain	Amino acid change	IC ₅₀ of RC21v3 (μM)		
		Assay 1	Assay 2	Average
CDR1 B	Wild type	1.1	1.1	1.1 (100)
C1	Q1226K	8.9	9.7	9.3 (68)
E1	V674F	6.2	5.5	5.9 (97)
R1	Q714K	4.9	4.3	4.6 (99)
R2	Q1445K	3.0	4.2	3.6 (99)

ATPase inhibition assays were performed in duplicate at pH 7.5 without ATP protection in two separate experiments of which Fig S5 is a representative example. The mean % inhibition of CaCdr1p by RC21v3 at 40 μM is given in brackets.